Latest filing published 15 Mar 2022 for OncoCyte Corp, €27k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Mitchell S. Levine: trading record in brief
This profile gathers the share dealings of Mitchell S. Levine in Insight Molecular Diagnostics Inc., where the filings describe the role as finance chief. Over a trading history stretching from 26 July 2018 to 15 March 2022, the count stands at 11 filings.
Purchases make up the whole of the open-market record (6 purchases, €91k). The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 3 share grants and 2 option exercises. So far in 2022, the count stands at 1 purchase and no sales.
In size, the median ticket on the buying side is €18k. On 1 out of 4 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The newest entry dates from 15 March 2022: an open-market purchase of €27k, in Insight Molecular Diagnostics Inc. The median gap between a trade and its publication by SEC (Form 4) is 5 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Mitchell S. Levine
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 25,000 shares@ US$1.166100.0% of flowCommon Stock, no par valueSEC:0001493152-22-006879:0Canonical exit: 13 Jun 2022 (T+90)
1 of 1 declaration
